Next-generation vaccines against Moderate inflammation gastrointestinal mucosal pathogens
Vax2Muc will develop next generation vaccines to overcome the antimicrobial resistance of gastrointestinal mucosal pathogens compromising global public health.
Therefore, Vax2Muc will develop, as a proof-of-concept, a prophylactic H. pylori vaccine candidate that will be evaluated in a phase I clinical trial. Moreover, it will advance GMP manufacturing, investigate and progress novel vaccine technologies and strategies for optimised mucosal immunity in the gastrointestinal tract.
Vax2Muc is funded by Horizon Europe and will run for 5 years, with planned completion in June 2028.
START
01 July ‘23
DURATION
60 MONTHS
BUDGET
€8,467,081.25
£209,396
10 PARTNERS
8 COUNTRIES
Team
The Vax2Muc consortium includes world-leading experts, that are perfectly placed to reach the project´s ambitious objectives. Together they aim to evaluate new technologies with the potential to close existing gaps in the prevention of bacterial infections.
